5,6,7,7a-tetrahydrothieno[3,2-c]pyridin-2(4H)-one Hydrochloride CAS 115473-15-9

Product Description:

Product Name: 5,6,7,7a-tetrahydrothieno[3,2-c]pyridin-2(4H)-one hydrochloride CAS NO:115473-15-9

Synonyms:

2H,4H,5H,6H,7H,7AH-Thieno[3,2-c]pyridin-2-one hydrochloride;

5,6,7,7a-tetrahydro-4H-thieno[3,2-c]pyridin-2-one,hydrochloride;

Chemical & Physical Properties:

Appearance :White to light yellow powder

Assay :≥99.0%

Boiling Point:364.3℃ at 760 mmHg

Flash Point:147.1℃

Melting Point: 207-210℃

2H,4H,5H,6H,7H,7AH-Thieno[3,2-c]pyridin-2-one hydrochloride is used to prasugrel intermediate.

Prasugrel is a thienopyridine antiplatelet drug developed by Eli Lilly and Japanese pharmaceutical manufacturer Daiichi Sankyo (Daiichi Sankyo). It is a prodrug that is metabolized by cytochrome P450 in the liver to form an active molecule. Platelet P2Y12 receptor binds to exert anti-platelet aggregation activity.

Prasugrel also has a stronger performance than clopidogrel in stable angina and acute coronary syndrome intervention, but the stronger the antiplatelet effect, the more likely it is to cause bleeding. The key issue now is how to identify high-risk patients with thromboembolism clinically and how to identify high-risk populations with bleeding risk, so that prasugrel and clopidogrel can be used differently in the two high-risk populations, both reducing coronary thrombosis and avoiding Major bleeding.

If you are interested in our products or have any questions, please feel free to contact us!

Products under patent are offered for R & D purpose only. However, the final responsibility lies exclusively with the buyer.